Option chain shows key data for Swedish Orphan Biovitrum's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Swedish Orphan Biovitrum.

Swedish Orphan Biovitrum (OTC:BIOVF) Stock, Option Chain

Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) on long-acting hemophilia factor replacement programs in 2006. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016, and Altuvoct in 2024. Sobi has been building its immunology pipeline (rare disease drug Gamifant, US rights to RSV antibodies Synagis and Beyfortus, gout drug SEL-212, complement drug Aspaveli) and a broader hematology pipeline (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo).

bz_pharma_briefs

Biotech

Large Cap

News

Health Care

General

BIOVF

Merck announces positive results from Phase 2b/3 and interim Phase 3 trials of a monoclonal antibody designed to protect infants from RSV.

Merck Virus Treatment Shows 60.4% Effectiveness, Reduces Certain Infections In Infants

Genetic,Research,And,Biotech,Science,Concept.,Human,Biology,And,Pharmaceutical

Equities

Movers

Trading Ideas

APLS

SWOBY

Swedish Orphan Biovitrum and Apellis Pharmaceuticals released topline results from the Phase 3 VALIANT study of pegcetacoplan for C3 glomerulopathy and IC-MPGN. The study met primary and secondary endpoints, showing proteinuria and kidney inflammation reductions.

Apellis Pharmaceuticals&#39; Pegcetacoplan Meets Primary Goal In Late-Stage Study In Patients With Rare Kidney Diseases

As the respiratory virus season kicks off, healthcare providers are racing against time to offer Pfizer Inc&#39;s (NYSE: PFE) vaccine, Abrysvo, to pregnant patients and Sanofi SA&#39;s (NASDAQ: 

Pfizer, Sanofi&#39;s Respiratory Syncytial Virus Products Faces Insurance And Logistical Hurdles To Protect Infants

SWEDISH ORPHAN BIOVIT ORD by Swedish Orphan Biovitrum AB

Swedish Orphan Biovitrum AB

Press Releases

Notice of Annual General Meeting in Swedish Orphan Biovitrum AB (publ)

Earnings

Sobi Q1 2024 report: Strong sales reflecting the strength of the portfolio

Sobi® receives positive CHMP opinion recommending approval of efanesoctocog alfa for once-weekly treatment of haemophilia A

Bulletin from Sobi's Annual General Meeting (AGM)

European Commission grants Sobi® Marketing Authorisation for ALTUVOCT™ for treatment of haemophilia A

Sobi initiates rolling biologics license application to FDA for SEL-212 for the potential treatment of chronic refractory gout

The Board of Directors of Sobi exercises authorisation for repurchase of shares for the purpose of securing the company's commitments under incentive programmes

Sobi Q2 2024 report: Strong delivery driven by robust portfolio performance

Sobi and Apellis announce positive topline results from phase 3 VALIANT study of pegcetacoplan in C3G and primary IC-MPGN

Sobi has completed issues of class C shares

Swedish Orphan Biovitrum

Comments

Swedish Orphan Biovitrum

Swedish Orphan Biovitrum (BIOVF) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga